Council for Innovation Promotion

C4IP Coalition Updates: October 2024

October was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. October Highlights: Spotlighting New Insights on Patent Quality On September 30, the nonprofit, nonpartisan Sunwater Institute released a policy report, “Patent Quality in the United States: Findings and Suggestions for Policymakers.” The report reviewed the U.S. […]

C4IP Coalition Updates: October 2024 Read More »

New Op-Ed from C4IP Co-Chair Andrei Iancu: Bill Is Key To Protecting US Economy From Patent Piracy

C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in Law360 highlighting the importance of passing the bipartisan RESTORE Patent Rights Act. This bill, introduced by Senators Chris Coons (D-DE) and Tom Cotton (R-AR) and Representatives Nathaniel Moran (R-TX) and Madeleine Dean (D-PA), would reinstate injunctions as the default remedy in

New Op-Ed from C4IP Co-Chair Andrei Iancu: Bill Is Key To Protecting US Economy From Patent Piracy Read More »

Fact Check: The RESTORE Patent Rights Act Would Bolster America’s Innovation Economy

The RESTORE Patent Rights Act, introduced in July by a bipartisan group of senators and representatives, would be a pivotal legislative milestone for promoting innovation, if enacted into law. This bill would reestablish injunctive relief as the default legal remedy for patent infringement, preventing patent infringers from using others’ IP and ultimately facing little more

Fact Check: The RESTORE Patent Rights Act Would Bolster America’s Innovation Economy Read More »

New Op-Ed from C4IP Co-Chairs Andrei Iancu and David Kappos: Proposed Drug Patent Reforms Would Do More Harm Than Good

C4IP Co-Chairs and former USPTO Directors Andrei Iancu and David Kappos recently published an opinion piece in RealClear Health highlighting the unintended consequences that would arise if the Medication Affordability and Patent Integrity Act (MAPIA) is passed by Congress and signed into law. Supporters of the bill argue that drug companies take advantage of a

New Op-Ed from C4IP Co-Chairs Andrei Iancu and David Kappos: Proposed Drug Patent Reforms Would Do More Harm Than Good Read More »

C4IP Coalition Updates: September 2024

September was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. September Highlights: Advancing the Patent Eligibility Restoration Act The Patent Eligibility Restoration Act (PERA) remains one of the most important innovation policy reforms on the legislative agenda. This bill would promote research and investment in high-tech

C4IP Coalition Updates: September 2024 Read More »

Fact Check: The Medication Affordability and Patent Integrity Act Would Unnecessarily Overhaul a Well-Functioning Patent System

The Medication Affordability and Patent Integrity Act, introduced by Senators Maggie Hassan (D-NH) and Mike Braun (R-IN), would require life sciences innovators to share volumes of unnecessary and confidential information related to drug approval with the USPTO. Under the bill, firms would also have to provide lengthy certifications stating that all information submitted to the

Fact Check: The Medication Affordability and Patent Integrity Act Would Unnecessarily Overhaul a Well-Functioning Patent System Read More »

Scroll to Top